milrinone
in review
2 min read
Updated 2026-10-30
maintenance
0.125–0.5 mcg/kg/min
no loading dose · low end in renal impairment
- HR
- ↑
- CO
- ↑↑
- SVR
- ↓
- PVR
- ↓↓
milrinone
PDE3 inhibitor inodilator: raises contractility and lowers SVR, PCWP and PVR, independent of β-receptors. Used for low-output HF or cardiogenic shock in β-blocked patients and for RV failure with high PVR. It’s long-acting and renally cleared, so hypotension lingers, particularly in AKI. Usually needs norepinephrine alongside.
mechanism
Inhibits phosphodiesterase-3 → ↑ cAMP in myocardium (inotropy, lusitropy) and vascular smooth muscle (arterial and pulmonary vasodilation). Acts downstream of the β-receptor.
dosing
| setting | dose |
|---|---|
| maintenance | 0.125–0.5 mcg/kg/min (ACC 2025); up to 0.75 (ESC) |
| loading dose | usually omitted (causes hypotension) |
| renal impairment | start at the low end and titrate slowly; clearance falls with eGFR |
| onset / half-life | 5–15 min / ~2–2.5 h (much longer in AKI) |
key points
- β-blocked patient: works where dobutamine is blunted (ESC: PDE3i or levosimendan may be preferred)
- RV failure / pulmonary hypertension: lowers PVR, which makes it attractive (dobutamine is the other option); combine with norepinephrine ± vasopressin to hold systemic pressure → right heart failure
- not for septic shock: vasodilation worsens vasoplegia, and the long half-life makes it hard to undo. Dobutamine is the inotrope there → septic shock
- vs dobutamine: equivalent outcomes (DOREMI (2021)); choose on BP, renal function, β-blockade and PVR → dobutamine
- hypotension doesn’t resolve minutes after stopping (unlike dobutamine) → have norepinephrine ready
- bridge only: no survival benefit in HF → cardiogenic shock
adverse effects
- hypotension (vasodilation), worse with a bolus, hypovolaemia or AKI
- atrial and ventricular arrhythmias
- accumulation in renal failure → prolonged hypotension
evidence
- DOREMI (2021) — milrinone vs dobutamine in cardiogenic shock (n=192): no difference in the composite primary outcome or its components, including in-hospital death
Prepared 2026-10-30. Not yet verified — check every number against the sources.